Navigation Links
Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
Date:5/20/2013

by targeting the hormone-producing enteroendocrine cells in the lower gut, NewMet may have better tolerability with the preserved efficacy of metformin at a lower dose. This would make NewMet ideal for the millions of Type 2 diabetes patients who have difficulty tolerating metformin or are unable to take the medication due to contraindications. I am eager to see the results of the additional planned clinical studies of NewMet to further understand this attractive profile."

Dr. DeFronzo is a world-renowned clinician, teacher and investigator who led the trials that supported the U.S. Food and Drug Administration approval of metformin in 1994. He and fellow investigators will be presenting the Elcelyx-sponsored NewMet Phase 2a trial results at the 2013 American Diabetes Association Scientific Sessions in June.

This randomized, double-blind, dose-finding Phase 2b trial is evaluating NewMet once-daily doses of 1,000, 800 and 600 milligrams compared to placebo. There are also two comparator arms with generic extended-release metformin dosed once-daily at 1,000 and 2,000 milligrams. The primary endpoint of the study is fasting plasma glucose at 4 weeks of treatment. Secondary endpoints through 12 weeks include changes in fasting plasma glucose, hemoglobin A1c, weight and measures of safety and tolerability. 

"Our research has been eye opening for physicians and endocrinologists who appreciate the clinical benefits of metformin such as glucose control and weight loss but are frustrated by its gastrointestinal side effects, need for titration and exclusion of patients with moderate and severe impaired kidney function. Type 2 diabetes patients who have difficulty tolerating generic metformin either come off of it completely or drop down to a less than maximally effective dose," explained Alain Baron , M.D., President and Chief Executive Officer of Elcelyx Therapeutics. "The goal of this study is to demonstrate that N
'/>"/>

SOURCE Elcelyx Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
2. Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
3. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
4. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
5. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
8. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
9. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
10. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
11. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Global Multiple Sclerosis Drugs Market 2014-2018" ... is a chronic, inflammatory medical condition that results in ... damaged because of an abnormal response by the immune ... (CNS). It is a potentially debilitating disease in which ...
(Date:8/29/2014)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... to the medical, research and veterinary markets, announced today ... Officer, will present at the CL King 12 th ... 9, 2014 at 12:30 p.m. ET. The conference will ... New York City . ...
(Date:8/29/2014)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the Company") today ... financial statements.  The Company recently changed its fiscal year ... application to list its common stock on a national ... DelMar,s financial statements as filed with the United States ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... 5, 2011 Ridge Diagnostics, Inc., a neurodiagnostic ... the 6th Annual Neurotech Investing and Partnering Conference to be ... on May 9th and 10th.   Ms. Williams, ... entitled "Next Generation Psychiatry" lead by Dr. Manuel Lopez-Figueroa, Vice ...
... Taking the right dose is vital to ensuring that ... any harm. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... droppers, or syringes designed to measure the proper dose. But ... there have been accidental overdoses. Find out how ...
Cached Medicine Technology:Ridge Diagnostics, Inc. CEO to Speak at Neurotech Investing and Partnering Conference 2
(Date:8/30/2014)... Seattle, WA (PRWEB) August 30, 2014 One ... of this era is the gluten-free diet. Originally meant for ... has become a catchall for people who are looking to ... gluten. However, not only is this kind of information erroneous, ... of health problems because of a drastic change in ...
(Date:8/30/2014)... August 30, 2014 August 28th, 2014: ... pain in our society and the toll that takes ... it’s vital that continuing education for physical therapists addresses ... help physical therapists help others, Hands-On Seminars is offering ... , Three learning styles are available to fit ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 When a prominent ... ensue, as happened on Wednesday, August 27th, when news began ... on JPMorgan Chase & Co and at least one ... is actually investigating attacks on seven prominent banks , ... may be affected, and the buzz quickly goes viral. ...
(Date:8/30/2014)... August 30, 2014 As 500 Zoloft lawsuits ... when give to pregnant mothers, Wright & Schulte LLC recently ... M. Rufe. The remand in the Zoloft lawsuits ... 18 states and are involved in one SSRI lawsuit ... have their Zoloft birth defect lawsuit sent back to the ...
(Date:8/30/2014)... August 30, 2014 Barton Associates, an ... locum tenens company , announces a new office location ... Barton Associates is headquartered in Peabody, MA, with additional ... Austin, TX; and Jupiter, FL. , Barton Associates made ... the physician shortage crisis affecting the United States, a ...
Breaking Medicine News(10 mins):Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 3Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 4Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 5Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 2Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 3Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 4Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 5Health News:Barton Associates to Open a New Office Location in Keene, NH 2
... Colonic lipomas have been found in related literature. One ... 14 issue of the World Journal of Gastroenterology because ... discussed age and sex factors, clinical and histopathological findings, ... and previously available literature. , The article reported ...
... Food and Drug Administration (FDA) has awarded the ... $1 million Orphan Products Development grant to study ... skin or internal organs., The unique, interdisciplinary, and ... Drolet, M.D., professor of dermatology and pediatrics, at ...
... Researchers at the Board of Governors Gene Therapeutics Research ... first time that it is possible to sustain therapeutic ... to a year, even in the presence of an ... humans. , The researchers demonstrated in an animal ...
... to be a multi-stage, multi-mechanism process by animal and ... Helicobacter pylori (H pylori) in the formation of gastric ... on November 7 in the World Journal of Gastroenterology ... H pylori on gastric cancer. , Gap junctions ...
... long-term outcomes, researchers say , THURSDAY, Oct. 25 (HealthDay News) ... peptide (ANP) can lessen cardiac injuries after heart attack and ... a Japanese study in this week,s issue of The ... damaged heart muscle (infarct) and lessened what,s known as "reperfusion ...
... 26 AMICAS, Inc (Nasdaq: AMCS ),announces the following Webcast: ... Inc Webcast, When: November 1, 2007 @ 8:30 AM ... over the Internet -- Simply log on to the web at ... Contact: Lisa Gould of AMICAS, Inc, 617-779-7892. If you ...
Cached Medicine News:Health News:The largest colonic lipoma to date 2Health News:Medical College of Wisconsin receives FDA grant 2Health News:Medical College of Wisconsin receives FDA grant 3Health News:Helicobacter pylori inhibits intercellular communication of cultured gastric cells 2
This compact, easy-to-operate analyzer delivers basic blood gas, ISEs with direct measured total hemoglobin and saturated oxygen. Use it as a cost effective backup for the central lab or for remote p...
... performance and rapid, small volume sample ... rotor. DiscoveryTMM120 SE processes sample sizes ... with a small floor footprint, brushless ... imbalance detection, thermo-electric cooling, and automatic ...
... Efficiency, versatility, and environmental ... the Optima LE-80 K Ultracentrifuge ... Coulters innovative Optima centrifugation technology, ... to cost effectively provide advanced ...
... small-volume samples. With the ability to provide ... (fat particles in lipemic samples), the Airfuge ... Lipemic samples can be cleaned in 10 ... The easy-to-operate tabletop centrifuge: Reaches top speed ...
Medicine Products: